BioMrieux Competitors

Pink Sheets . USA . 
Stock . bioMrieux SA
BMXMF Stock  USD 112.57  1.47  1.32%   
bioMrieux SA competes with Mainz Biomed, Neuronetics, Prenetics Global, Fonar, and IQVIA Holdings; as well as few others. The company classifies itself under Healthcare sector and is part of Diagnostics & Research industry. Analyzing BioMrieux competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of BioMrieux to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out BioMrieux Correlation with its peers.

BioMrieux vs Agilent Technologies Correlation

Very weak diversification

The correlation between bioMrieux SA and A is 0.59 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding bioMrieux SA and A in the same portfolio, assuming nothing else is changed.

Moving together with BioMrieux Pink Sheet

  0.61IDXX IDEXX LaboratoriesPairCorr

Moving against BioMrieux Pink Sheet

  0.88PEP PepsiCoPairCorr
  0.73MTGRF Mount Gibson Iron Earnings Call TomorrowPairCorr
  0.7RIBS Southern ConceptsPairCorr
  0.63SOUHY South32 ADRPairCorr
  0.61HGKGY Power Assets HoldingsPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
110.78112.57114.36
Details
Intrinsic
Valuation
LowRealHigh
101.31117.07118.86
Details

BioMrieux Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BioMrieux and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of BioMrieux and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of bioMrieux SA does not affect the price movement of the other competitor.

High positive correlations

ICLR
+ 0.87
IQV
TWST
+ 0.86
PRE
TWST
+ 0.81
FONR
WAT
+ 0.81
IQV
ICLR
+ 0.79
WAT
FONR
+ 0.67
PRE
  

High negative correlations

FONR
- 0.73
APDN
WAT
- 0.56
PRE
TWST
- 0.52
APDN
STIM
- 0.49
APDN
WAT
- 0.46
TWST
IQV
- 0.44
APDN

Risk-Adjusted Indicators

There is a big difference between BioMrieux Pink Sheet performing well and BioMrieux Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BioMrieux's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
MYNZ  4.54 (0.74) 0.00 (0.28) 0.00 
 0.00 
 9.48 
(8.33)
 26.72 
APDN  5.54  0.66  0.09  1.65  6.49 
(6.78)
 15.72 
(9.55)
 68.08 
STIM  5.90 (0.57) 0.00 (0.09) 0.00 
 0.00 
 10.95 
(12.22)
 35.51 
PRE  3.83  0.94  0.23  0.56  3.61 
(4.26)
 9.77 
(6.74)
 22.19 
FONR  1.20  0.37  0.31 (192.91) 0.48 
(1.61)
 1.96 
(1.98)
 27.57 
IQV  1.64 (0.44) 0.00 (0.22) 0.00 
 0.00 
 3.30 
(4.70)
 15.97 
MTD  1.12 (0.15) 0.00 (0.07) 0.00 
 0.00 
 2.51 
(2.40)
 7.69 
TWST  3.11  0.61  0.21  0.28  2.91 
(3.74)
 7.70 
(4.95)
 17.96 
WAT  1.23 (0.28) 0.00 (0.19) 0.00 
 0.00 
 3.25 
(2.08)
 18.00 
ICLR  3.05 (0.77) 0.00 (0.18) 0.00 
 0.00 
 4.72 
(7.24)
 45.92 

BioMrieux Competitive Analysis

The better you understand BioMrieux competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BioMrieux's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BioMrieux's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BMXMF MYNZ APDN STIM PRE FONR IQV MTD TWST WAT
 1.32 
 112.57 
BioMrieux
 6.67 
 0.80 
Mainz
 19.57 
 5.62 
Applied
 10.13 
 1.42 
Neuronetics
 4.82 
 21.97 
Prenetics
 0.05 
 18.55 
Fonar
 1.13 
 166.94 
IQVIA
 0.22 
 1,361 
Mettler
 3.04 
 49.11 
Twist
 1.11 
 323.37 
Waters
Market Volatility
(90 Days Market Risk)
Very steady
Risky
Very steady
Dangerous
Not too volatile
Not too volatile
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Solid
Fair
Weakest
Weakest
Solid
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Risky
Hazard
Risky
Low
Tiny
Small
Tiny
Low
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Not Available
Buy
Strong Buy
Strong Sell
Strong Buy
Buy
Strong Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Buy
Not Rated
Strong Buy
Buy
Strong Hold
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Current Ratio
2.02
10.83
2.16
4.02
5.05
8.01
0.9
1.13
6.58
2.1
Net Asset
4.62 B
13.24 M
12.79 M
140.9 M
213.57 M
216.91 M
29.94 B
3.71 B
641.86 M
5.08 B
Profit Margin
0.16
N/A
N/A
-0.34
-0.6
0.0708
0.0834
0.22
-0.2
0.2
EBITDA
1.01 B
(19.56 M)
(13.33 M)
(34.37 M)
(51.57 M)
16.3 M
3.46 B
1.23 B
(52.1 M)
802.59 M
Operating Margin
0.21
-28.22
-12.14
-0.2
-0.26
0.12
0.15
0.31
-0.32
0.34
Current Valuation
11.99 B
8.43 M
901.73 K
159.85 M
346.25 M
102.33 M
42.12 B
29.75 B
2.91 B
32.54 B
Price To Book
3.18
2.87
0.73
3.56
2.28
0.67
4.35
3980.99
6.59
12.38
Retained Earnings
86 M
(90.98 M)
(309.67 M)
(419.79 M)
(517.07 M)
(5.29 M)
7.42 B
9.24 B
(1.32 B)
9.79 B
Current Asset
1.06 B
N/A
11.35 M
N/A
N/A
45.56 M
2.28 B
862.82 M
N/A
3.21 B
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.16
0.26
0.13
0.81
0.35
0.99
1.36
1.44
2.27
1.18
Number Of Employees
12.08 K
19
46
716
285
535
93 K
16.6 K
979
7.9 K
Shares Outstanding
118.37 M
5.41 M
1.29 M
68.49 M
15.25 M
6.17 M
169.6 M
20.33 M
61.31 M
98.09 M
Cash Flow From Operations
811.1 M
(17.09 M)
(13.71 M)
(31 M)
(28.87 M)
11.26 M
2.65 B
955.77 M
(47.63 M)
652.55 M
Annual Yield
0.0087
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
362.8 M
3.27 M
739.16 K
82.63 M
5.77 M
38.92 M
16.17 B
2.34 B
137.32 M
2.52 B
Return On Equity
0.18
-4.66
-1.37
-2.19
-0.3
0.0584
0.21
0.3
-0.17
0.29
Z Score
19.8
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.1
-1.14
-0.64
-0.21
-0.15
0.0296
0.0503
0.2
-0.13
0.12
Book Value Per Share
29.31
0.62
8.06
0.4
11.61
27.78
38.34
-1.16
7.44
43.01
Number Of Shares Shorted
N/A
322.53 K
196.51 K
8.59 M
110 K
11.69 K
4.56 M
537.62 K
12.17 M
2.25 M
Current Liabilities
644 M
N/A
4.08 M
N/A
N/A
20.61 M
1.91 B
595.13 M
N/A
564.08 M
Total Asset
4.62 B
13.24 M
12.79 M
140.9 M
213.57 M
216.91 M
29.94 B
3.71 B
641.86 M
5.08 B
Debt To Equity
0.17
0.1
0.15
0.63
0.068
0.26
2.37
N/A
0.12
4.0
Last Dividend Paid
0.85
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Short Ratio
N/A
0.08
0.8
6.48
0.47
1.53
3.85
4.2
9.52
4.72
Target Price
N/A
14.0
1.5
6.5
33.5
N/A
246.1
1501.38
49.89
402.71
Shares Owned By Institutions
18.4
6.91
6.92
60.52
12.28
47.42
98.96
99.56
98.46
60.22
Market Capitalization
12.05 B
7.9 M
7.26 M
97.25 M
369.72 M
92.74 M
28.43 B
27.8 B
3.01 B
31.72 B
Price To Earning
23.91
N/A
-5.06
N/A
144.87
12.1
103.68
38.4
N/A
40.43
Price To Earnings To Growth
2.84
N/A
N/A
N/A
N/A
N/A
0.94
2.84
-0.04
3.58
Price To Sales
3.63
10.98
1.94
0.75
4.8
1.11
1.74
6.91
7.69
10.02
Net Income
601.1 M
(21.65 M)
(7.09 M)
(43.73 M)
(49.81 M)
10.67 M
1.36 B
869.19 M
(77.67 M)
642.63 M
Earnings Per Share
4.99
-5.28
-57.12
-0.83
-3.59
1.11
7.85
42.05
-1.27
10.77
Shares Owned By Insiders
64.28
1.37
1.1
19.12
18.18
4.61
1.06
0.44
1.54
0.1
Revenue
3.38 B
893.99 K
3.43 M
74.89 M
30.62 M
104.35 M
16.31 B
4.03 B
376.57 M
3.17 B
Working Capital
412 M
1.89 M
5.65 M
26.86 M
49.6 M
127.55 M
(1.13 B)
164.55 M
241.56 M
879.35 M
Cash And Equivalents
524.2 M
26.01 M
4.68 M
73.7 M
176.27 M
48.73 M
1.98 B
66.89 M
504.97 M
587.83 M
Cash Per Share
4.43
1.8
0.36
2.71
1.59
7.31
7.32
5.48
8.93
7.01
Gross Profit
1.96 B
445.43 K
1.25 M
66.1 M
35.74 M
43.31 M
5.43 B
2.39 B
202.13 M
1.88 B
Day Typical Price
112.57
0.79
5.37
1.48
21.87
18.55
168.3
1363.51
48.97
321.11
Accumulation Distribution
N/A
0.12
0.21
0.15
0.0452
0.0016
0.0392
0.019
0.0508
0.0361
Market Facilitation Index
N/A
0.1
1.26
0.24
1.01
0.03
6.75
26.14
2.55
11.78
Daily Balance Of Power
9.2 T
0.5
0.7302
(0.67)
1.0
0.3333
(0.28)
0.1159
0.5686
0.3005
Period Momentum Indicator
1.47
0.05
0.92
(0.16)
1.01
0.01
(1.91)
3.03
1.45
3.54
Rate Of Daily Change
1.01
1.07
1.2
0.9
1.05
1.0
0.99
1.0
1.03
1.01
Day Median Price
112.57
0.79
5.24
1.51
21.83
18.55
168.98
1364.79
48.9
319.98
Price Action Indicator
0.73
0.035
0.84
(0.17)
0.65
0.01
(2.99)
(2.32)
0.94
5.16
Coefficient Of Variation
(961.68)
(942.73)
1353.82
(2,297)
477.98
920.31
(786.00)
(2,153)
519.74
(1,096)
Mean Deviation
0.8176
4.54
5.54
5.9
3.83
1.2
1.64
1.12
3.11
1.23
Jensen Alpha
(0.21)
(0.74)
0.6605
(0.57)
0.936
0.3666
(0.44)
(0.15)
0.6085
(0.28)
Total Risk Alpha
(0.33)
(1.03)
(0.01)
(0.91)
0.672
0.1091
(0.54)
(0.19)
0.4698
(0.38)
Sortino Ratio
N/A
N/A
0.0916
N/A
0.2254
0.3066
N/A
N/A
0.2138
N/A
Downside Variance
N/A
N/A
46.63
N/A
19.2
1.0
N/A
N/A
11.07
N/A
Standard Deviation
1.82
5.66
9.41
7.68
5.05
3.47
2.62
1.45
4.06
2.24
Kurtosis
10.93
(0.04)
7.69
0.9119
0.3793
54.61
8.14
0.3459
1.23
21.5
Potential Upside
1.58
9.48
15.72
10.95
9.77
1.96
3.3
2.51
7.7
3.25
Treynor Ratio
(0.80)
(0.28)
1.65
(0.09)
0.5635
(192.91)
(0.22)
(0.07)
0.2838
(0.19)
Maximum Drawdown
12.27
26.72
68.08
35.51
22.19
27.57
15.97
7.69
17.96
18.0
Variance
3.31
31.98
88.62
58.93
25.55
12.01
6.87
2.1
16.5
5.01
Market Risk Adjusted Performance
(0.79)
(0.27)
1.66
(0.08)
0.5735
(192.90)
(0.21)
(0.06)
0.2938
(0.18)
Risk Adjusted Performance
(0.08)
(0.08)
0.0687
(0.03)
0.1772
0.0954
(0.1)
(0.03)
0.1633
(0.07)
Skewness
(2.48)
0.5202
1.79
0.5844
0.5141
7.08
(2.19)
0.1394
0.4158
(3.35)
Semi Deviation
N/A
N/A
6.49
N/A
3.61
0.4798
N/A
N/A
2.91
N/A
Information Ratio
(0.14)
(0.12)
0.0664
(0.05)
0.1954
0.0885
(0.15)
(0.09)
0.1752
(0.12)
Value At Risk
(2.99)
(8.33)
(9.55)
(12.22)
(6.74)
(1.98)
(4.70)
(2.40)
(4.95)
(2.08)
Expected Short fall
N/A
N/A
(6.78)
N/A
(4.26)
(1.61)
N/A
N/A
(3.74)
N/A
Downside Deviation
N/A
N/A
6.83
N/A
4.38
1.0
N/A
N/A
3.33
N/A
Semi Variance
N/A
N/A
42.15
N/A
13.07
0.2302
N/A
N/A
8.45
N/A

BioMrieux Competition Performance Charts

Five steps to successful analysis of BioMrieux Competition

BioMrieux's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by bioMrieux SA in relation to its competition. BioMrieux's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of BioMrieux in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BioMrieux's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to bioMrieux SA, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your BioMrieux position

In addition to having BioMrieux in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Education Thematic Idea Now

Education
Education Theme
Companies involved in apprenticeship, education, tutoring, schooling, online universities, and other learning services. The Education theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Education Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in BioMrieux Pink Sheet

BioMrieux financial ratios help investors to determine whether BioMrieux Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMrieux with respect to the benefits of owning BioMrieux security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY